Last 12 months
Inside the activity.
0 purchase rows · 17 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2021 Filed Jun 30, 2021 21:00 UTC |
Coffin RobertDirector · President & Chief R&D Officer
|
SaleCommon Stock | 14,663 | $40.04 | $587,106.52 |
DisclosureSEC source: 0001104659-21-087803 · tm2121160-1_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,806,320 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:47 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 12,200 | $34.53 | $421,266.00 |
DisclosureSEC source: 0001104659-21-082229 · tm2119957-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.29 to $34.75. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 865,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 290,523 of which are exercisable as of the date hereof. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:47 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 17,800 | $33.80 | $601,640.00 |
DisclosureSEC source: 0001104659-21-082229 · tm2119957-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,009 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.29 to $34.27. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 10, 2021 Filed May 12, 2021 01:01 UTC |
Lewis TanyaChief Dev. Oper. Off.
|
GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $33.99 | $0.00 |
DisclosureSEC source: 0001104659-21-064730 · tm2115949-1_4seq1.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Chief Dev. Oper. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-05-10 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on May 10, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| May 10, 2021 Filed May 12, 2021 01:01 UTC |
Lewis TanyaChief Dev. Oper. Off.
|
GrantCommon Stock | 73,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-064730 · tm2115949-1_4seq1.xml · nonDerivative · entry 1 Lewis Tanya · CIK 0001451038 · Chief Dev. Oper. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,333 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| May 03, 2021 Filed May 6, 2021 01:02 UTC |
Patel SushilChief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001104659-21-061913 · tm2115244-2_4seq1.xml · derivative · entry 2 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-05-03 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on May 3, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| May 03, 2021 Filed May 6, 2021 01:02 UTC |
Patel SushilChief Commercial Officer
|
GrantCommon Stock | 88,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061913 · tm2115244-2_4seq1.xml · nonDerivative · entry 1 Patel Sushil · CIK 0001860609 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,333 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 18:35 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 2,700 | $29.98 | $80,946.00 |
DisclosureSEC source: 0001104659-21-052071 · tm2113387-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,809 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.76 to $30.17. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 895,809 shares of the Issuer's common stock. The reporting person also holds options to acquire 503,578 shares of the Issuer's common stock, 274,077 of which are exercisable as of the date hereof. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 18:35 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 27,300 | $30.69 | $837,837.00 |
DisclosureSEC source: 0001104659-21-052071 · tm2113387-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,509 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $31.19. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:19 UTC |
Pirzkall AndreaChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 30,750 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046732 · tm2112099-13_4seq1.xml · derivative · entry 2 Pirzkall Andrea · CIK 0001818578 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,750 Underlying: Common Stock · 30,750 shares Expires 2031-04-01 F3 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:19 UTC |
Pirzkall AndreaChief Medical Officer
|
GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046732 · tm2112099-13_4seq1.xml · nonDerivative · entry 1 Pirzkall Andrea · CIK 0001818578 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. F2 · balance_after: 1,000 shares of the Issuer's common stock are held by the Reporting Person's husband. The Reporting Person may be deemed to be the beneficial owner of such shares. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:13 UTC |
Weinand DieterDirector
|
GrantStock Option (right to buy) · Derivative | 24,750 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046722 · tm2112099-4_4seq1.xml · derivative · entry 1 Weinand Dieter · CIK 0001744419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,750 Underlying: Common Stock · 24,750 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:35 UTC |
Omega Fund IV, L.P.Director · 10% owner
Omega Fund IV GP, L.P.10% owner
Omega Fund IV G.P. Manager, Ltd.10% owner
Stampacchia OtelloDirector
Paster Anne-Mari10% owner
|
GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0000899243-21-014749 · doc4.xml · derivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · Director · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director Paster Anne-Mari · CIK 0001652863 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires not disclosed F1 · derivative.exercise_date: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2021 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. F1 · derivative.expiration_date: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2021 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. F1 · balance_after: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2021 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. F1 · ownership.direct: The Common Stock Options (the "Options") were granted to Otello Stampacchia in his capacity as a director of the issuer on April 1, 2021 (the "Grant Date"), with the Options vesting on the first anniversary of the Grant Date. The Options expire on the tenth anniversary of the Grant Date. The Options are held directly by Mr. Stampacchia. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:11 UTC |
Dhingra KapilDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046718 · tm2112099d1_4.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:14 UTC |
Lewis TanyaDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046724 · tm2112099-6_4seq1.xml · derivative · entry 1 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:14 UTC |
Pucci PaoloDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046723 · tm2112099-5_4seq1.xml · derivative · entry 1 Pucci Paolo · CIK 0001436861 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:17 UTC |
Astley-Sparke PhilipDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 128,125 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046728 · tm2112099-10_4seq1.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,125 Underlying: Common Stock · 128,125 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:17 UTC |
Astley-Sparke PhilipDirector · Chief Executive Officer
|
GrantCommon Stock | 85,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046728 · tm2112099-10_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,340,712 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:11 UTC |
SLATTERY JOSEPH PDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046719 · tm2112099-2_4seq1.xml · derivative · entry 1 SLATTERY JOSEPH P · CIK 0001246530 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:15 UTC |
Levitsky HyamDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046725 · tm2112099-7_4seq1.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:17 UTC |
Love ColinChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 58,925 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046727 · tm2112099-9_4seq1.xml · derivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,925 Underlying: Common Stock · 58,925 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:17 UTC |
Love ColinChief Operating Officer
|
GrantCommon Stock | 39,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046727 · tm2112099-9_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,809 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:18 UTC |
Coffin RobertDirector · President & Chief R&D Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 115,300 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046729 · tm2112099-11_4seq1.xml · derivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,300 Underlying: Common Stock · 115,300 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:18 UTC |
Coffin RobertDirector · President & Chief R&D Officer
|
GrantCommon Stock | 76,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046729 · tm2112099-11_4seq1.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,820,983 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:16 UTC |
Rhodes Jason PDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046726 · tm2112099-8_4seq1.xml · derivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: This option was granted on April 1, 2021 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2022. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:19 UTC |
Franchi Jean M.Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 69,050 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046731 · tm2112099-12_4seq1.xml · derivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,050 Underlying: Common Stock · 69,050 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:19 UTC |
Franchi Jean M.Chief Financial Officer
|
GrantCommon Stock | 46,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046731 · tm2112099-12_4seq1.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,035 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:20 UTC |
Esposito PamelaChief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 51,250 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046734 · tm2112099-14_4seq1.xml · derivative · entry 2 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,250 Underlying: Common Stock · 51,250 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:20 UTC |
Esposito PamelaChief Business Officer
|
GrantCommon Stock | 34,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046734 · tm2112099-14_4seq1.xml · nonDerivative · entry 1 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,159 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:12 UTC |
Slootweg Hugo AlexanderDirector
|
GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046721 · tm2112099-3_4seq1.xml · derivative · entry 1 Slootweg Hugo Alexander · CIK 0001744922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:07 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 100 | $32.67 | $3,267.00 |
DisclosureSEC source: 0001104659-21-037933 · tm219986-1_4seq1.xml · nonDerivative · entry 3 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 886,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 236,023 of which are exercisable as of the date hereof. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:07 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 18,518 | $33.22 | $615,167.96 |
DisclosureSEC source: 0001104659-21-037933 · tm219986-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886,624 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.69 to $33.67. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:07 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 11,382 | $34.06 | $387,670.92 |
DisclosureSEC source: 0001104659-21-037933 · tm219986-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,142 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.68 to $34.67. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 11,380 | $35.84 | $407,859.20 |
DisclosureSEC source: 0001104659-21-025336 · tm217197-1_4seq1.xml · nonDerivative · entry 2 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.18 to $36.12. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 916,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 229,189 of which are exercisable as of the date hereof. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:58 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 18,620 | $36.61 | $681,678.20 |
DisclosureSEC source: 0001104659-21-025336 · tm217197-1_4seq1.xml · nonDerivative · entry 1 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,904 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.13 to $37.12. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 16:50 UTC |
Omega Fund IV, L.P.10% owner
Omega Fund IV GP, L.P.10% owner
Omega Fund IV G.P. Manager, Ltd.10% owner
Stampacchia OtelloDirector · 10% owner
|
SaleCommon Stock | 5,249 | $45.00 | $236,205.00 |
DisclosureSEC source: 0000899243-21-005869 · doc4.xml · nonDerivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,141,321 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.90 to $45.53 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.direct: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 14:27 UTC |
Omega Fund IV, L.P.Director · 10% owner
Omega Fund IV GP, L.P.10% owner
Omega Fund IV G.P. Manager, Ltd.10% owner
Stampacchia OtelloDirector · 10% owner
|
SaleCommon Stock | 3,393 | $46.04 | $156,213.72 |
DisclosureSEC source: 0000899243-21-003569 · doc4.xml · nonDerivative · entry 2 Omega Fund IV, L.P. · CIK 0001528382 · Director · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,283,682 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.90 to $46.27 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.direct: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 14:27 UTC |
Omega Fund IV, L.P.Director · 10% owner
Omega Fund IV GP, L.P.10% owner
Omega Fund IV G.P. Manager, Ltd.10% owner
Stampacchia OtelloDirector · 10% owner
|
SaleCommon Stock | 26,957 | $45.34 | $1,222,230.38 |
DisclosureSEC source: 0000899243-21-003569 · doc4.xml · nonDerivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · Director · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287,075 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.90 to $45.88 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.direct: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 22:08 UTC |
Rhodes Jason PDirector
|
SaleCommon Stock | 5,558 | $46.14 | $256,446.12 |
DisclosureSEC source: 0001209191-21-005901 · doc4.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 946,000 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.95 to $46.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 14:56 UTC |
Omega Fund IV, L.P.Director · 10% owner
Omega Fund IV GP, L.P.10% owner
Omega Fund IV G.P. Manager, Ltd.10% owner
Stampacchia OtelloDirector · 10% owner
|
SaleCommon Stock | 3,269 | $45.03 | $147,203.07 |
DisclosureSEC source: 0000899243-21-003262 · doc4.xml · nonDerivative · entry 2 Omega Fund IV, L.P. · CIK 0001528382 · Director · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,314,032 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.90 to $45.17 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.direct: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 14:56 UTC |
Omega Fund IV, L.P.Director · 10% owner
Omega Fund IV GP, L.P.10% owner
Omega Fund IV G.P. Manager, Ltd.10% owner
Stampacchia OtelloDirector · 10% owner
|
SaleCommon Stock | 8,090 | $45.05 | $364,454.50 |
DisclosureSEC source: 0000899243-21-003262 · doc4.xml · nonDerivative · entry 1 Omega Fund IV, L.P. · CIK 0001528382 · Director · 10% owner Omega Fund IV GP, L.P. · CIK 0001528383 · 10% owner Omega Fund IV G.P. Manager, Ltd. · CIK 0001624456 · 10% owner Stampacchia Otello · CIK 0001361712 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,317,301 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F1 · price: Shares were sold pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.90 to $45.46 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.direct: The reported securities are held directly by Omega Fund IV, L.P. ("Omega IV"). The reported securities may be deemed to be beneficially owned by each of Omega Fund IV GP, L.P. ("Omega IV GP"), as the general partner of Omega IV, and Omega Fund IV GP Manager, Ltd. ("Omega IV GP Manager"), as the general partner of Omega IV GP. Otello Stampacchia and Anne-Mari Paster are all the shareholders and directors of Omega IV GP Manager and have shared voting and investment power over the shares held by Omega IV. Each of Omega IV GP, Omega Fund IV GP Manager and the Omega Directors disclaims beneficial ownership of the securities reported herein, except to the extent of its or their pecuniary interest therein, if any. Otello Stampacchia is a director of the issuer. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:00 UTC |
Coffin RobertDirector · President & Chief R&D Officer
|
SaleCommon Stock | 29,803 | $43.99 | $1,311,033.97 |
DisclosureSEC source: 0001104659-21-007820 · tm213368d7_4.xml · nonDerivative · entry 2 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,744,118 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.41 to $44.37. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,744,118 shares of the Issuer's common stock. The reporting person also holds options to acquire 977,599 shares of the Issuer's common stock, 483,771 of which are exercisable as of the date hereof. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:00 UTC |
Coffin RobertDirector · President & Chief R&D Officer
|
SaleCommon Stock | 30,197 | $44.87 | $1,354,939.39 |
DisclosureSEC source: 0001104659-21-007820 · tm213368d7_4.xml · nonDerivative · entry 1 Coffin Robert · CIK 0001376492 · Director · President & Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773,921 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 16, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.38 to $45.37. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:53 UTC |
Astley-Sparke PhilipDirector · Chief Executive Officer
|
SaleCommon Stock | 7,632 | $42.40 | $323,596.80 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 8 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,255,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.04 to $42.85. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F9 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,255,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 647,571 shares of the Issuer's common stock, 230,907 of which are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:53 UTC |
Astley-Sparke PhilipDirector · Chief Executive Officer
|
SaleCommon Stock | 800 | $43.15 | $34,520.00 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 7 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,929 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 21:47 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 7,157 | $42.38 | $303,313.66 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 5 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,524 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.03 to $42.83. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F7 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 946,524 shares of the Issuer's common stock. The reporting person also holds options to acquire 444,653 shares of the Issuer's common stock, 224,438 of which are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 19, 2021 21:47 UTC |
Love ColinChief Operating Officer
|
SaleCommon Stock | 700 | $43.25 | $30,275.00 |
DisclosureSEC source: 0001104659-21-005568 · tm213368-4_4seq1.xml · nonDerivative · entry 4 Love Colin · CIK 0001376493 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953,681 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 12, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC |
Esposito PamelaChief Business Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,727 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · derivative · entry 10 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,203 Underlying: Common Stock · 5,727 shares Expires 2025-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC |
Esposito PamelaChief Business Officer
|
SaleCommon Stock | 5,127 | $42.38 | $217,282.26 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 7 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,994 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.76. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F4 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 175,994 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 497,852 shares of the Issuer's common stock, 458,852 of which are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:50 UTC |
Esposito PamelaChief Business Officer
|
SaleCommon Stock | 600 | $43.24 | $25,944.00 |
DisclosureSEC source: 0001104659-21-005570 · tm213368-5_4seq1.xml · nonDerivative · entry 6 Esposito Pamela · CIK 0001744425 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,121 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.